Petlife Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PTLF research report →
About the company
Based in Los Angeles, California, Petlife Pharmaceuticals, Inc. is dedicated to the discovery, formulation, commercialization, and ongoing support of both medicinal drugs and nutritional supplements for pets. Their primary focus is on addressing canine and feline cancer and various autoimmune conditions, such as arthritis, within the United States market.
- CEO
- Sebastian Serrell-Watts
- IPO
- 2008
- Employees
- 1
- HQ
- Los Angeles, CA, US
Price Chart
- Market Cap
- $39.35K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.01
- EV/EBITDA
- -0.03
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 1007.59%
- ROIC
- 3410.55%
- Revenue
- $0 · 0.00%
- Net Income
- $-23,256,850 · -530.77%
- EPS
- $-0.33 · 17.50%
- Op Income
- $-22,655,379
- FCF YoY
- -110.04%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 3.91
- Avg Volume
- 282
Get TickerSpark's AI analysis on PTLF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our PTLF coverage
Recent articles, reports, and earnings notes.
No research on PTLF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PTLF report →Similar companies
Peers in the same neighborhood.